Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Cannabis Bioscience International Holdings (CBIH) Cash & Equivalents (2022 - 2025)

Cannabis Bioscience International Holdings' Cash & Equivalents history spans 4 years, with the latest figure at $132.0 for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 86.83% year-over-year to $132.0; the TTM value through Nov 2025 reached $132.0, down 86.83%, while the annual FY2025 figure was $12952.0, 1615.5% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $132.0 at Cannabis Bioscience International Holdings, down from $223.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $25655.0 in Q1 2023 and bottomed at $132.0 in Q4 2025.
  • The 4-year median for Cash & Equivalents is $969.0 (2024), against an average of $6239.6.
  • The largest annual shift saw Cash & Equivalents crashed 98.6% in 2023 before it skyrocketed 1615.5% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $24089.0 in 2022, then tumbled by 98.6% to $337.0 in 2023, then surged by 197.33% to $1002.0 in 2024, then tumbled by 86.83% to $132.0 in 2025.
  • Per Business Quant, the three most recent readings for CBIH's Cash & Equivalents are $132.0 (Q4 2025), $223.0 (Q3 2025), and $12952.0 (Q2 2025).